Literature DB >> 22373660

Continuous furosemide infusion in the management of ascites.

Nicholas A Rogers1, Samir Gupta, Jennifer A Cuthbert.   

Abstract

BACKGROUND: The current therapy for patients hospitalized with ascites requires titration of oral diuretics and often needs several days. A faster method for predicting the response to a given dose of diuretic may allow this process to be completed more rapidly. AIM: The objective of this study was to describe the short-term safety and efficacy of a diuretic infusion to predict net sodium excretion in patients with cirrhosis, ascites, and edema using a fractional excretion of sodium (FENa) of 1% or greater as the target.
METHODS: We conducted a retrospective case series of patients admitted for management of ascites who received intravenous furosemide by continuous infusion in ascites management. Patients were stratified depending on whether they had edema or received an intravenous bolus of furosemide or a large-volume paracentesis. The primary outcome was the proportion of patients achieving a FENa of 1% or greater during the infusion. Secondary outcomes included development of electrolyte abnormalities or acute kidney injury during or immediately following the infusion and natriuresis on titrated oral furosemide.
RESULTS: Forty-seven patients meeting criteria were identified from 721 patients seen in consultation. Ten of the patients had edema and received neither bolus intravenous diuretic therapy nor therapeutic paracentesis; all 10 achieved a FENa of 1% or greater. One patient had transient hypokalemia. Of 37 patients who either had no edema or received additional treatment options, all but 6 patients achieved a FENa of 1% or greater. Transient complications in 31 patients with natriuresis included hyponatremia (n = 1), hypokalemia (n = 5), and acute kidney injury (n = 3). Twenty-four-hour urine sodium averaged more than 4 g/d on the titrated oral furosemide regimen in 19 patients completing the collection.
CONCLUSIONS: Use of a short continuous furosemide infusion can achieve a FENa of 1% or greater in patients with cirrhotic ascites and may be safe and efficacious for diuresis, meriting further study.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22373660      PMCID: PMC3310244          DOI: 10.2310/JIM.0b013e31824963f1

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  12 in total

1.  Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease.

Authors:  Kenneth Berman; Sweta Tandra; Kate Forssell; Raj Vuppalanchi; Raj Vuppalanch; James R Burton; James Nguyen; Devonne Mullis; Paul Kwo; Naga Chalasani
Journal:  Clin Gastroenterol Hepatol       Date:  2010-11-17       Impact factor: 11.382

2.  Management of adult patients with ascites due to cirrhosis: an update.

Authors:  Bruce A Runyon
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

3.  Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion.

Authors:  T P Dormans; J J van Meyel; P G Gerlag; Y Tan; F G Russel; P Smits
Journal:  J Am Coll Cardiol       Date:  1996-08       Impact factor: 24.094

4.  Intravenous infusion of frusemide as treatment for ascites in malignant disease.

Authors:  S A Amiel; A M Blackburn; R D Rubens
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-07

5.  Diuretic strategies in patients with acute decompensated heart failure.

Authors:  G Michael Felker; Kerry L Lee; David A Bull; Margaret M Redfield; Lynne W Stevenson; Steven R Goldsmith; Martin M LeWinter; Anita Deswal; Jean L Rouleau; Elizabeth O Ofili; Kevin J Anstrom; Adrian F Hernandez; Steven E McNulty; Eric J Velazquez; Abdallah G Kfoury; Horng H Chen; Michael M Givertz; Marc J Semigran; Bradley A Bart; Alice M Mascette; Eugene Braunwald; Christopher M O'Connor
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

6.  Natural history of patients hospitalized for management of cirrhotic ascites.

Authors:  Ramon Planas; Silvia Montoliu; Belen Ballesté; Monica Rivera; Mireia Miquel; Helena Masnou; Jose Antonio Galeras; María D Giménez; Justiniano Santos; Isabel Cirera; Rosa María Morillas; Susanna Coll; Ricard Solà
Journal:  Clin Gastroenterol Hepatol       Date:  2006-11       Impact factor: 11.382

7.  Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients.

Authors:  Ramon Planas; Belén Ballesté; Marco Antonio Alvarez; Monica Rivera; Silvia Montoliu; Josep Anton Galeras; Justiniano Santos; Susanna Coll; Rosa Maria Morillas; Ricard Solà
Journal:  J Hepatol       Date:  2004-05       Impact factor: 25.083

8.  Immediate effects of furosemide on renal hemodynamics in chronic liver disease with ascites.

Authors:  G Daskalopoulos; G Laffi; T Morgan; M Pinzani; H Harley; T Reynolds; R D Zipser
Journal:  Gastroenterology       Date:  1987-06       Impact factor: 22.682

9.  Compensated cirrhosis: natural history and prognostic factors.

Authors:  P Ginés; E Quintero; V Arroyo; J Terés; M Bruguera; A Rimola; J Caballería; J Rodés; C Rozman
Journal:  Hepatology       Date:  1987 Jan-Feb       Impact factor: 17.425

10.  Diuresis in the ascitic patient: a randomized controlled trial of three regimens.

Authors:  M R Fogel; V K Sawhney; E A Neal; R G Miller; C M Knauer; P B Gregory
Journal:  J Clin Gastroenterol       Date:  1981       Impact factor: 3.062

View more
  2 in total

1.  Vasopressin antagonist efficacy and safety in volume-overloaded critically ill patients: a new therapeutic alternative.

Authors:  Jesús Ruiz-Ramos; Paula Ramírez; María Jesús Broch; Mónica Gordon; Esther Villarreal; Armando Pinos; Manuel Sosa; Álvaro Castellanos-Ortega
Journal:  Eur J Hosp Pharm       Date:  2018-11-10

2.  Continuous versus intermittent use of furosemide in patients with heart failure and moderate chronic renal dysfunction.

Authors:  Zhigui Zheng; Xinxin Jiang; Jianguo Chen; Dongyuan He; Xiaohui Xie; Yunan Lu
Journal:  ESC Heart Fail       Date:  2021-03-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.